Drug Profile
VBY 036
Alternative Names: VBY-036Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Virobay
- Class Analgesics; Antidementias; Small molecules
- Mechanism of Action Cathepsin S inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Neuropathic pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in USA (PO)
- 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease in USA (PO)
- 01 Nov 2013 Virobay completes a phase I trial in Neuropathic pain (in volunteers) in USA (NCT01892891)